ES2264533T3 - Asociacion de un antitrombotico y de aspirina y su utilizacion para el tratamiento de enfermedades aterotromboticas. - Google Patents

Asociacion de un antitrombotico y de aspirina y su utilizacion para el tratamiento de enfermedades aterotromboticas.

Info

Publication number
ES2264533T3
ES2264533T3 ES03745819T ES03745819T ES2264533T3 ES 2264533 T3 ES2264533 T3 ES 2264533T3 ES 03745819 T ES03745819 T ES 03745819T ES 03745819 T ES03745819 T ES 03745819T ES 2264533 T3 ES2264533 T3 ES 2264533T3
Authority
ES
Spain
Prior art keywords
compound
association
aspirin
pharmaceutically acceptable
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03745819T
Other languages
English (en)
Spanish (es)
Inventor
Tony Verbeuren
Gilbert Lavielle
Bernard Cimetiere
Marie-Odile Vallez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2264533T3 publication Critical patent/ES2264533T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES03745819T 2002-04-05 2003-04-04 Asociacion de un antitrombotico y de aspirina y su utilizacion para el tratamiento de enfermedades aterotromboticas. Expired - Lifetime ES2264533T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204222 2002-04-05
FR0204222A FR2838057B1 (fr) 2002-04-05 2002-04-05 Nouvelle association d'un antithrombotique et d'aspirine

Publications (1)

Publication Number Publication Date
ES2264533T3 true ES2264533T3 (es) 2007-01-01

Family

ID=28052120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03745819T Expired - Lifetime ES2264533T3 (es) 2002-04-05 2003-04-04 Asociacion de un antitrombotico y de aspirina y su utilizacion para el tratamiento de enfermedades aterotromboticas.

Country Status (26)

Country Link
US (1) US7618955B2 (cg-RX-API-DMAC7.html)
EP (1) EP1496884B1 (cg-RX-API-DMAC7.html)
JP (1) JP4065853B2 (cg-RX-API-DMAC7.html)
KR (1) KR100645143B1 (cg-RX-API-DMAC7.html)
CN (1) CN1297265C (cg-RX-API-DMAC7.html)
AR (1) AR039253A1 (cg-RX-API-DMAC7.html)
AT (1) ATE329591T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003246774B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309019A (cg-RX-API-DMAC7.html)
CA (1) CA2480697A1 (cg-RX-API-DMAC7.html)
CY (1) CY1105106T1 (cg-RX-API-DMAC7.html)
DE (1) DE60306133T2 (cg-RX-API-DMAC7.html)
DK (1) DK1496884T3 (cg-RX-API-DMAC7.html)
EA (1) EA006978B1 (cg-RX-API-DMAC7.html)
ES (1) ES2264533T3 (cg-RX-API-DMAC7.html)
FR (1) FR2838057B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20074101B (cg-RX-API-DMAC7.html)
MA (1) MA27114A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009760A (cg-RX-API-DMAC7.html)
NO (1) NO20044700L (cg-RX-API-DMAC7.html)
NZ (1) NZ535430A (cg-RX-API-DMAC7.html)
PL (1) PL371620A1 (cg-RX-API-DMAC7.html)
PT (1) PT1496884E (cg-RX-API-DMAC7.html)
UA (1) UA79457C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003084525A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407593B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376994C2 (ru) * 2005-07-22 2009-12-27 Дзе Проктер Энд Гэмбл Компани Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
EP2155195B1 (en) 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
JP2009001537A (ja) * 2007-06-25 2009-01-08 Lab Servier 血管障害の処置を目的とする医薬の入手における抗アテローム血栓化合物の使用
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
NO20044700L (no) 2004-10-29
MA27114A1 (fr) 2004-12-20
NZ535430A (en) 2006-09-29
CN1297265C (zh) 2007-01-31
AU2003246774B2 (en) 2007-02-15
US7618955B2 (en) 2009-11-17
GEP20074101B (en) 2007-05-10
DE60306133D1 (de) 2006-07-27
KR100645143B1 (ko) 2006-11-10
AR039253A1 (es) 2005-02-16
WO2003084525A1 (fr) 2003-10-16
FR2838057A1 (fr) 2003-10-10
CN1646111A (zh) 2005-07-27
HK1076034A1 (en) 2006-01-06
AU2003246774A1 (en) 2003-10-20
EP1496884A1 (fr) 2005-01-19
KR20040098053A (ko) 2004-11-18
CY1105106T1 (el) 2009-11-04
EA200401293A1 (ru) 2005-02-24
EA006978B1 (ru) 2006-06-30
JP2005528376A (ja) 2005-09-22
CA2480697A1 (fr) 2003-10-16
US20050143354A1 (en) 2005-06-30
ZA200407593B (en) 2006-07-26
UA79457C2 (en) 2007-06-25
MXPA04009760A (es) 2004-12-13
EP1496884B1 (fr) 2006-06-14
DE60306133T2 (de) 2007-01-04
FR2838057B1 (fr) 2005-07-08
ATE329591T1 (de) 2006-07-15
PL371620A1 (en) 2005-06-27
DK1496884T3 (da) 2006-10-02
JP4065853B2 (ja) 2008-03-26
BR0309019A (pt) 2005-02-01
PT1496884E (pt) 2006-09-29

Similar Documents

Publication Publication Date Title
JP7838004B2 (ja) Polybromo-1(pbrm1)の小分子分解剤
ES2749096T3 (es) Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados
AR069911A1 (es) Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
AU2011270719B2 (en) Niacin mimetics, and methods of use thereof
MX2014001101A (es) Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados.
JP2016532667A (ja) ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
ES2714563T3 (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatía hepática
CA2671550A1 (en) Heterocycle compounds and methods of use thereof
AR040580A1 (es) Derivados de pirazol heterobiciclico como inhibidores de la quinasa
WO2008125600A3 (en) Pyrazole derivatives as p2x7 modulators
JPH04346927A (ja) 脳内グルタミン酸遊離抑制剤
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
AR078537A1 (es) Derivados heterociclicos de indol ligandos del receptor de estrogenos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades asociadas al sistema nervioso central, osteoporosis, canceres y otras patologias
ES2238316T3 (es) Uso de derivados de carbonilamino contra trastornos del snc.
Chen et al. Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors
CN101328135A (zh) 羧酸化合物
JP4065853B2 (ja) 抗血栓剤とアスピリンとの新規な組み合わせ及びアテローム血栓性疾患を処置するためのその使用
ES2314457T3 (es) Asociacion de un antagonista de los receptores tp y de clopidogrel.
ES2365905T3 (es) Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico.
ES2329614T3 (es) Derivados de benzotriazol como antagonistas de los receptores cannabinoides.
JP2005528376A5 (cg-RX-API-DMAC7.html)
BRPI0616219A2 (pt) amidas de Ácidos alcanàicos substituÍdas por o-heterociclos saturados
CA3009534C (en) 3-aryl-quinoxalinone derivatives and use thereof as cftr regulators
TH104852A (th) สารประกอบที่มอดูเลทเซอทูอิน
TH83468A (th) ยาต้านฤทธิ์ของตัวรับ crf และวิธีการที่เกี่ยวข้องกับเรื่องนี้